ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study

A. Zuckermann,1 M. Rinaldi,1 N. Yonan,1 S.-S. Wang,1 G. Dong,2 P. Lopez.2

1For the A2309 Study Group, Vienna, Austria
2Novartis, Basel, Switzerland.

Meeting: 2015 American Transplant Congress

Abstract number: 75

Keywords: Adverse effects, Heart transplant patients, Immunosuppression

Session Information

Session Name: Concurrent Session: "The Pit and the Pendulum": VADs, Dual Organs and Other Matters of the Heart

Session Type: Concurrent Session

Date: Sunday, May 3, 2015

Session Time: 2:15pm-3:45pm

 Presentation Time: 3:27pm-3:39pm

Location: Room 119-B

Purpose: In the A2310 (NCT00300274) heart transplant (HTx) study with everolimus (EVR) vs mycophenolate mofetil (MMF), information on a broad spectrum of potential wound healing events (WHE), spanning from incision site pain to mediastinitis, were collected prospectively. WHE occurred in 1/3 of patients in all arms with no significantly increased risk for patients on EVR vs MMF. In a post-hoc analysis, clinically relevant WHE, defined by surgical experts, was evaluated to assess a potential increased risk with EVR for critical WHE. Methods: This 24 month (M), open-label, multicenter study randomized 721 HTx recipients to EVR1.5mg (C0 3-8ng/mL; N=282) or EVR3mg (C0 6-12ng/mL; N=168)+reduced cyclosporine (rCsA) or MMF3g (N = 271)+standard (s) CsA; with steroids±induction. Enrollment into the EVR3mg arm was stopped early due to higher mortality. Detailed data were collected on location (sternal/non-sternal), symptoms, degree, diagnosis and intervention on WHE using special case report forms and results were published. Subsequently, the list of reported WHE was reviewed by the surgical experts and those events not considered as clinically relevant were excluded for this post-hoc analysis. WHE reported as serious adverse event, mediastinitis, osteomyelitis, or events requiring surgical debridement, vacuum assisted closure (VAC) or sternal rewiring were considered as critical. Results: Overall, 23.7%, 24.6% and 20.5% of patients experienced at least one clinically relevant WHE in EVR1.5mg, 3mg and MMF arms, respectively. Incidence of sternal and non-sternal WHE was similar across all the arms. Incidence of critical WHE was numerically higher with EVR (1.5mg: 10.0% and 3mg: 15.0%) vs MMF (9.0%) arms, but with overall low incidences for mediastinitis, and wound dehiscence. The patients requiring surgical debridement, rewiring or VAC for sternal WHE between EVR1.5mg and MMF arms was not significantly different (Table). Conclusions: Patients treated with EVR1.5mg up to 12M experienced a comparable incidence of clinically relevant WHE vs MMF. Higher doses of EVR may increase the incidence of WHE.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Zuckermann A, Rinaldi M, Yonan N, Wang S-S, Dong G, Lopez P. Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/clinically-relevant-wound-events-with-everolimus-based-immunosuppressive-regimen-post-hoc-analysis-from-a-randomized-heart-transplant-study/. Accessed June 6, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences